R

Roche

Global pharmaceuticals and diagnostics company

P&OG Consulting Lead - Diagnostics

Full-TimeUpdated
No salary listed
Expert
Welwyn, UK+1 moreMore locations: Mannheim, Germany
In PersonBasel or Rotkreuz is preferred; other European locations may be considered at the hiring manager’s discretion.
People & HRHR Generalist & Employee Relations

About the job

Requirements
  • A minimum of 10 years of relevant consulting experience in a global organization of similar size and complexity.
  • Proven senior stakeholder management skills in a highly complex and matrix environment.
  • Outstanding networking and interpersonal skills.
  • An excellent track record of partnering and collaboration within People and Culture and with other parts of the organization.
  • Exceptional systems thinking and an enterprise mindset.
  • Formal or informal leadership experience.
  • Demonstrated courage and the ability to face ambiguous situations, push back, and challenge the status quo.
  • Fluent English language skills.
Responsibilities
  • Co-lead the Consulting Area of Practice with the Practice Lead and other Consulting Leads.
  • Build the brand and advocate for the Consulting practice.
  • Provide leadership and develop strategies to achieve short- and long-term outcomes toward the Roche 2030 Ambitions.
  • Design, lead, and execute large-scale and complex change and transformation initiatives.
  • Lead the Consulting Points of Contact for Diagnostics.
  • Partner with the BP Chapter Lead and Business People Enablement partners for Diagnostics, the Divisional Strategy and Strategy Implementation team, and key business leaders.
  • Develop collaborative partnerships with transformation offices and other teams working on transformation and organizational effectiveness across Roche, acting as a system-wide link.
  • Participate as a member of the Diagnostics People and Culture Enabling Team.
Desired Qualifications
  • Experience in an internal consulting practice or a large external consultancy in organizational development, management, and/or leadership.
  • Knowledge of agile principles and methodologies applied in an enterprise-wide context.
  • Languages other than English.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 29th, 2026
HER2 targeted therapies market to hit $16.34B by 2030 on 8.6% CAGR

The global HER2 targeted therapies market is forecast to grow from $10.84 billion in 2025 to $11.75 billion in 2026, according to a Research and Markets report. It is expected to reach $16.34 billion by 2030, a compound annual growth rate (CAGR) of 8.6% from 2026. Demand for targeted cancer treatments, rising breast and gastric cancer rates, and wider use of monoclonal antibody therapies are driving growth. Precision oncology, broader biomarker testing, and next-generation antibody-drug conjugates should support it further. In February 2026, Boehringer Ingelheim won US Food and Drug Administration approval for HERNEXEOS (zongertinib) for HER2-mutant advanced non-small cell lung cancer. In December 2023, Pfizer bought Seagen for about $43 billion. North America led the market in 2025; Asia-Pacific is expected to grow fastest.

Yahoo Finance
Oct 28th, 2026
Roche launches BAP1 test to distinguish mesothelioma from other cancers

Roche has launched the VENTANA BAP1 (SP527) test worldwide to help diagnose mesothelioma, a rare and deadly cancer. The automated immunohistochemistry assay helps pathologists tell mesothelioma apart from other cancers, including non-small cell lung cancer, and from benign tissue growth. The test is registered as a Class I IVD with the US Food and Drug Administration and has IVDR approval as a Class C device. Roche announced the launch in Basel on October 28, 2026. Most patients are diagnosed late, with median overall survival of just 12 to 18 months. BAP1 works alongside the recently launched MTAP and Claudin-4 tests, which help preserve limited tissue samples for molecular sequencing. "Timely differential diagnosis of mesothelioma is critical to help deliver the best outcome for patients," said Matt Sause, chief executive officer of Roche Diagnostics.

Yahoo Finance
Oct 27th, 2026
Zymeworks signs Roche deal worth up to $718M in milestones, shows 65% response in ovarian cancer

Zymeworks has agreed a collaboration with Roche on ZW209, a T-cell engager that targets DLL3-positive tumours, including small cell lung cancer. The deal is subject to Hart-Scott-Rodino Act clearance. Zymeworks would receive $55 million upfront and $40 million when a Phase 1b study begins. It could also earn up to $718 million in milestones, plus tiered royalties from high single digits to mid-teens. Roche would fund research and development, and take over later development and commercialisation. Zymeworks will run the first global trial. Zymeworks also reported updated data for ZW191 in platinum-resistant ovarian cancer. In high-grade serous disease, confirmed response rates were 65% at 6.4 mg/kg and 55% at 9.6 mg/kg. The company is seeking partners to fund further development.

Yahoo Finance
Oct 27th, 2026
Roche wins CE Mark for compact cobas smart e immunoanalyser with 100+ planned assays

Roche has received the CE Mark for its cobas smart e immunoanalyser, a compact testing platform for smaller hospitals and laboratories. The company announced the approval in Basel on October 27, 2026. The device fits in a footprint of under one square metre and has a planned menu of over 100 assays. Reaction times are 18 minutes or less for more than 90% of Roche immunoassays, which can help local facilities cut turnaround times. It uses the same reagents and Elecsys technology as Roche's high-throughput systems, so results stay consistent across sites. Roche says it needs one minute of daily operator input and cuts hands-on maintenance by up to two-thirds compared with earlier platforms. It joins the cobas e 402 and cobas e 801 units, completing a range for clinics through to large hospital laboratories.

Yahoo Finance
Oct 26th, 2026
Zymeworks licenses ZW209 to Roche in deal worth up to $813M, with $55M upfront

Zymeworks has granted Roche exclusive worldwide rights to develop and commercialise ZW209, a DLL3-targeting trispecific T-cell engager. The deal brings $55.0 million upfront, up to $758.0 million in further milestones, and tiered royalties. Roche will take on most later development and commercialisation work. That fits Zymeworks' partnership-heavy, capital-light model, though future cash from ZW209 now depends largely on Roche meeting its own targets. The company also reported Phase 1 data for ZW191, an ovarian cancer antibody-drug conjugate. It showed activity across folate receptor alpha expression levels and a more favourable tolerability profile at 6.4mg/kg.